Selinexor: First Global Approval

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

(2019) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy and safety of selinexor in recurrent glioblastoma.

(2019) Andrew B. Lassman et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

(2019) Michael Shafique et al.   ONCOLOGIST

A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

(2019) N. Kalakonda et al.   HEMATOLOGICAL ONCOLOGY

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer

(2018) Xiao X. Wei et al.   ONCOLOGIST

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death

(2018) Christian Argueta et al.   Oncotarget

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents

(2018) Trinayan Kashyap et al.   Oncotarget

Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM)

(2018) Sundar Jagannath et al.   Clinical Lymphoma Myeloma & Leukemia

A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).

(2018) Sosana Delimpasi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).

(2018) Eoghan Ruadh Malone et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.

(2018) Bhavana Bhatnagar et al.   JOURNAL OF CLINICAL ONCOLOGY

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

(2018) Nizar J. Bahlis et al.   BLOOD

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma

(2017) Barbara Muz et al.   Translational Oncology

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone

(2016) Irfana Muqbil et al.   CANCER LETTERS

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells

(2016) Cheryl Taylor-Kashton et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia

(2016) Thomas B. Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

(2016) Albiruni R. Abdul Razak et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

(2016) Mrinal M. Gounder et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

(2016) Joel G. Turner et al.   Journal of Hematology & Oncology

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

(2016) Trinayan Kashyap et al.   Oncotarget

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

(2016) Joel G. Turner et al.   Oncotarget

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

(2015) Z. A. Hing et al.   BLOOD

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds

(2015) Marsha Crochiere et al.   BMC CANCER

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor

(2015) S. Rosebeck et al.   MOLECULAR CANCER THERAPEUTICS

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

(2014) Y Zhong et al.   LEUKEMIA